International journal of hematology
Impact of diagnosis-to-treatment interval in relapsed or refractory diffuse large B-cell lymphoma.
Keita Ishii, Kazuhito Suzuki, Tadahiro Gunji, Ryoko Fukushima, Hiroto Ishii, Hideki Uryu, Hirofumi Yamauchi, Kurumi Tsukamoto, Kei Hirano, Riku Nagao, Takashi Nakamura, Takeshi Saito, Kaichi Nishiwaki, Shingo Yano
Published: 202610.1007/s12185-026-04168-4
Abstract
The diagnosis-to-treatment interval (DTI) has been identified as a prognostic factor in newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, its significance in relapsed or refractory DLBCL (R/R DLBCL) remains unclear. This study aimed to…
Preview only. Read the full abstract at the source